Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §2

Draft conflicts-of-interest policy — submissions

The 12 submissions received, published in full with declared interests and secretariat responses.

Document identifier
CEI-CP-010/2
Series
Public comment period
Version
1.0
Published
01 Apr 2023
Last reviewed
01 Apr 2023
Next review
01 Apr 2024
Identifier
10.71829/cei.cp.10
Certainty
Not rated
Cycle
2023 Q1
Window
26 Jan 2023 – 23 Mar 2023
Status
Closed
Submissions
12

§2Submissions and responses

12 submissions were received. Each is published in full below with its declared interest, the secretariat response and the disposition. The Institute publishes submissions it did not accept in the same form as those it did.

Dr Rukayat Zaleski-Mbeki, MD, PhD, FESC ISO/IEC 17025-accredited contract testing laboratory
DRAFT-CONFLICTS-PO/009 received 27 Jan 2023

The Institute publishes no telephone number and no messaging channel

The respondent states that a body inviting submissions ordinarily provides a channel for questions about the process, and that the written address alone is a high barrier for a first-time respondent.

The respondent asks that a route for procedural questions be provided.

Declared interest. No financial or non-financial interest to declare in relation to the subject of this consultation.
Secretariat responseNoted, no amendment16 Apr 2023

The secretariat notes this submission. The written route is the only route and that is a deliberate constitutional position rather than an omission.

No amendment arises. The Institute holds no telephone number and uses no messaging channel, because a submission made in writing is a document that can be published with its response and an oral exchange is not. Guidance on making a submission has been expanded so that the written route requires no prior enquiry to use.

Rosalind Petrossian, MSc (Clinical Trials) Regional hospital pharmacy department
DRAFT-CONFLICTS-PO/010 received 04 Feb 2023

An industry submission should be identifiable without reading the declared interest

The respondent states that a declared interest printed below a submission is read after the submission, and that a reader who has already absorbed the argument reads the declaration as an afterthought.

The respondent proposes that a submission made on behalf of a company be labelled at the head of the submission as well as in the declaration.

Declared interest. Has received travel support to attend a scientific meeting from a manufacturer of a compound named in the draft.
Secretariat responseAccepted04 Apr 2023

The secretariat accepts this submission. The order in which a reader encounters the two facts changes how the second is weighed.

A submission made on behalf of a company is now identified as an industry submission on its face, at the head of the submission and in the disposition table, in addition to the declared interest published in full beneath it.

Dr Ludmila Tollemache, PharmD, PhD University teaching hospital, department of endocrinology
DRAFT-CONFLICTS-PO/005 received 23 Feb 2023

Recusal should follow automatically from any declared financial interest

The respondent states that case-by-case recusal decisions require the body making them to judge its own members, and that an automatic rule removes the judgement and with it the appearance of partiality.

The respondent proposes automatic recusal on any declared financial interest in a named company.

Declared interest. Has previously served as an investigator on a trial included in the evidence base under consultation. Received no personal payment; institutional payment was made to the trial site.
Secretariat responseNot accepted04 Apr 2023

The secretariat does not accept this submission. An automatic rule of that breadth would recuse most of the people competent to assess the evidence, and the Institute would be left with assessors chosen for their distance from the field.

Recusal remains determined against the specific document, with the decision, its reasons and the person recused published in the document front matter. The submission is published in full because it identifies a genuine tension the Institute has resolved in one direction rather than removed.

Quentin Gwynne-Sarpong, MD, DPhil Metabolic medicine service, tertiary centre · industry submission
DRAFT-CONFLICTS-PO/003 received 27 Feb 2023

The document should not describe uses outside the approved indication

The submission is made on behalf of a marketing-authorisation holder. It states that the draft describes uses of the compound that fall outside the approved indication, that such uses are not supported by the sponsor, and that describing them may be read as legitimising them.

The sponsor asks that the sections concerned be removed, or in the alternative that they carry a prominent statement that the sponsor does not support such use.

Declared interest. Is an employee of a marketing-authorisation holder for a compound named in the draft. This submission is made on behalf of that company and is identified as an industry submission throughout.
Secretariat responseNot accepted29 Mar 2023

The secretariat does not accept this submission. The Institute records what is supplied and what is used, because a reader encountering a compound outside a regulated route is the reader most in need of an assessment of the evidence for it.

The sections remain. Every such section already states the regulatory status of the use described and states that the evidence for it is assessed separately from the evidence for the approved indication. The submission is published in full and identified as an industry submission.

Dr Wolfram Kaltenbach-Mensah, PhD (Toxicology) Health-technology assessment agency
DRAFT-CONFLICTS-PO/004 received 03 Mar 2023

Declared interests should appear on the document rather than on a separate page

The draft links to a central conflicts register. The respondent argues that a reader assessing whether to rely on a particular document should not have to leave it to find out who assessed it and what they declared.

The respondent proposes that the interests of every named contributor to a document be printed on that document.

Declared interest. Holds a patent relating to a delivery technology referenced in the draft.
Secretariat responseNoted, no amendment31 Mar 2023

The secretariat notes this submission and records that the draft already provides for it, which the respondent could reasonably have missed because the provision sits in an appendix.

Every document carries the declared interests of its named contributors in its front matter, and the central register exists so that a reader can see a person across all documents rather than one at a time. No amendment arises; the provision has been moved from the appendix into the body of the methodology document so that it is findable.

Dr Jolyon Grünbaum-Sowande, MD, FRCP Independent evidence-synthesis consultancy
DRAFT-CONFLICTS-PO/006 received 08 Mar 2023

The document is unreadable without specialist training

The respondent, a trustee of a patient organisation, states that the draft is written for a reader who already understands certainty grading, and that the people most affected by the subject matter will not reach the assessment at all.

The respondent proposes a plain-language summary at the head of every document, written to the same standard of accuracy as the document itself and not as a promotional abstract.

Declared interest. Is a practising clinician who prescribes compounds in the class under assessment. No financial relationship with any manufacturer.
Secretariat responseAccepted in part03 Apr 2023

The secretariat accepts this submission in part. A plain-language summary is added. The proposal that it replace the technical abstract is declined, because the abstract is the part of the document other assessors read and cite.

Every document now opens with a plain-language summary of not more than 150 words, placed above the technical abstract and carrying the same certainty language, so that the two cannot diverge.

Dr Hyacinth Oyelaran-Steen, PhD (Chemistry), MRSC University department of pharmacy practice
DRAFT-CONFLICTS-PO/011 received 13 Mar 2023

The search date is not on the face of the document

The draft carries a publication date and a review date but not the date on which the evidence was last searched. Those are three different dates and only the third tells a reader how current the assessment is. A document published in one quarter may rest on a search run two quarters earlier, and nothing on the page allows that gap to be measured.

The respondent proposes that the search date be printed adjacent to every certainty rating rather than in the methods section, on the ground that a reader who acts on a rating is unlikely to have read the methods section first.

Declared interest. Is a practising clinician who prescribes compounds in the class under assessment. No financial relationship with any manufacturer.
Secretariat responseAccepted29 Mar 2023

The secretariat accepts this submission. The distinction between publication, review and search dates is real and the draft did not make it visible where it mattered.

The search date is now printed adjacent to every certainty rating and is carried in the document metadata, so that the interval between the search and the reading is visible without reference to the methods section.

Dr Dmitri Nordhagen, PhD (Chemistry), MRSC University department of pharmacy practice
DRAFT-CONFLICTS-PO/007 received 14 Mar 2023

The secretariat answers submissions and is not itself named

The respondent states that responses are attributed to the secretariat as a body, and that a reader cannot tell who wrote a response or whether that person had a relevant interest.

The respondent proposes that responses be signed individually.

Declared interest. Has used a compound in the class under assessment under prescription. Declared at the Institute's request; the Institute regards a lived-experience declaration as an interest and not as a disqualification.
Secretariat responseAccepted in part18 Apr 2023

The secretariat accepts this submission in part. Responses are attributed to the named members of the secretariat responsible for the document rather than to individuals per response, and the interests of those members are published.

Every comment period now names the secretariat members responsible for it, with their declared interests, in the consultation front matter, so that the responses can be read against the interests of the people who wrote them.

Dr Ottoline Fitzgerald-Nwosu, MD, MRCP Independent analytical consultancy
DRAFT-CONFLICTS-PO/001 received 15 Mar 2023

The document should state what a reader ought to do

The draft assesses evidence and stops. The respondent, a practising clinician, states that a reader arriving at the document with a decision to make is left to convert an assessment into an action without help, and proposes that each document close with a recommendation.

The respondent argues that other evidence bodies issue recommendations and that declining to do so transfers the difficult part of the work to the reader.

Declared interest. Has received consultancy fees from a supplier named in the Institute's supplier assessment set within the preceding two years.
Secretariat responseNot accepted29 Mar 2023

The secretariat does not accept this submission, and records that the point is a reasonable one rather than a misunderstanding.

The Institute assesses evidence and does not issue recommendations, because a recommendation embeds values and a resource context that the Institute does not hold and cannot state. That constitutional limit is published on the methodology page and is not varied by consultation. The submission remains published in full.

Dr Amara Vandergraaf, MD, MRCP Independent analytical consultancy
DRAFT-CONFLICTS-PO/012 received 18 Mar 2023

Point estimates are given without an interval

Several estimates in the draft appear as single figures. The respondent states that a point estimate without an interval invites a precision the underlying data do not support, and that the effect is worst where the estimate is drawn from a small contributing set.

The respondent proposes that no point estimate appear anywhere in the document set without its interval, including in summary tables and in the abstract.

Declared interest. Has previously served as an investigator on a trial included in the evidence base under consultation. Received no personal payment; institutional payment was made to the trial site.
Secretariat responseAccepted in part24 Apr 2023

The secretariat accepts this submission in part. Intervals are added wherever the source reports one. The proposal is declined for figures the source published without an interval, because the Institute will not compute an interval a source did not report.

Every estimate now carries its interval where the source reported one, and where it did not, the estimate is annotated as reported without an interval rather than left to appear as a precise figure.

Dr Liesbeth Quenneville, MPharm, MRPharmS Academic nephrology unit
DRAFT-CONFLICTS-PO/008 received 19 Mar 2023

A party criticised in an assessment should have a right of reply

The respondent states that a supplier or sponsor whose documentation is assessed adversely has no route to respond other than a comment period that may not be open.

The respondent proposes a standing right of reply published alongside the assessment.

Declared interest. Is an employee of a marketing-authorisation holder for a compound named in the draft. This submission is made on behalf of that company and is identified as an industry submission throughout.
Secretariat responseAccepted in part29 Mar 2023

The secretariat accepts this submission in part. A route to submit a correction of fact is opened at any time and is not dependent on a consultation window. A general right of reply published alongside the assessment is not adopted, because it would give an assessed party the last word on the Institute's own document.

A standing correction route is now published, corrections of fact are assessed and applied at any time with the change recorded in the amendment log, and a submission of substance received outside a window is held and published in the next comment period on that document.

Dr Zebedee Zaleski-Mbeki, PhD (Pharmaceutics) Endocrine surgery service
DRAFT-CONFLICTS-PO/002 received 21 Mar 2023

The terms on which the documents may be reused are not stated

The respondent, a librarian, states that the site carries no statement of reuse terms and that an assessment which cannot be quoted with confidence will be paraphrased instead, which is worse for accuracy.

The respondent proposes an explicit reuse statement.

Declared interest. Is a member of the Institute's external reviewer register but did not review the document under consultation.
Secretariat responseAccepted29 Mar 2023

The secretariat accepts this submission. An unstated position on reuse is a position that will be guessed at.

The reuse terms are now stated explicitly on the legal page and in the document footer, permitting quotation and reproduction with attribution and the document version, and requiring that any reproduction carry the certainty rating that accompanied the quoted statement.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.